Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase StudyCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
Use of PSCO-524® (Antinol®) and Casting for Treatment of Tetraparesis and Neck Pain Due to Atlantoaxial Instability and Subluxation of the 1st-2nd Cervical Vertebrae
Authors:
A 7 months old male Pomeranian dog was admitted to Thong Lor animal hospital for signs of intermittent leg paresis and hyperesthesia during the past 2 weeks.
Physical examination found grade II tetraparesis, neck hyperflexion, spasm of cervical muscle, and cervical hyperesthesia.
X-ray examination showed atlantoaxial instability and dorsal subluxation of the first and second cervical vertebrae. The disease is congenital and commonly found in toy breed dogs (Itoh H. et al, ).
A cast was used to stabilize the joints for 12 weeks in conjunction with medicinal treatment including pain killer medicine, gabapentin, and 1 capsule of PSCO-524® (Antinol®) sid.
After one week of the treatment, the dog showed no sign of pain when touched but the signs of hind limb paresis still remained. The treatment was continued until the 10th week that gabapentin was terminated and no recurrence of pain was detected since then.
After 12 weeks of the treatment, the cast was removed and PSCO-524® (Antinol®) 1 capsule sid was continued and the dog did not show any progressive development of clinical signs.
Use of PCSO-524® with Physical Rehabilitation to Regain Mobility in Dogs after Femoral Head and Neck Excision
Authors:
An 8 years old Pomeranian dog showed acute non weight-bearing lameness of the right hind limb after high jumping. Preliminary examination identified pain at the right hip and radiographic images revealed right hip luxation.
Femoral head and neck excision was performed for the surgical treatment.
Multimodal treatment scheme deployed after the surgery consisted of neutraceutical PCSO-524® and physical rehabilitation using laser class 4, exercise such as Cavaletti exercise, balanced board, walking on treadmill, and hydrotherapy including walking under water and swimming.
Evaluation of the treatment during follow-up showed decreased pain score and severity of lameness, which was consistent with the owner’s report that described improvement of weight- bearing of the right hind limb and the quality of life.
Use of PCSO-524®(Antinol®) in a Pomeranian Dog with Degenerative Mitral Valve Disease (DMVD) and Cardiac Tumor of the Left Atrium
Authors:
A 10-year old Pomeranian dog with degenerative mitral valve disease (DMVD) and cardiac tumor of the left atrium was treated with pimobendan, ramipril, and furosemide in conjunction with PCSO-524® (Antinol®) as supplemental therapy.
After the treatment, the dog showed improved ability to conduct various activities, increased appetite and ingestion, weight gain and disappearance of paroxysmal ventricular premature contraction (VPC).
The C-reactive protein (CRP), which is an inflammatory marker in dogs, also decreased to normal level within 21 days of PCSO-524® (Antinol®) supplementation.
Use of PCSO-524® for Supplementary Treatment of Protein Losing Nephropathy in Animals
Authors:
An intact male Shih Tzu dog weighed 5.8 kilograms was referred to Suvarnachad Animal Hospital with signs of polydipsia, polyuria, edema and ascites due to accumulation of fluid in the abdominal cavity.
Biochemical tests found hypoalbuminemia, hyperglobulinemia, hypercholesterolemia, increased urine protein creatinine ratio (UPC) to 5.88 and no signs of inflammation or infection of the urinary tract.
Protein losing nephropathy from glomerular disease was diagnosed based on the biochemical indicators. Medication was given to the dog in order to control kidney damage and minimize the clinical symptoms.
Anti-proteinuric drug, for example ACE inhibitor to reduce blood pressure, was particularly selected for the treatment in conjunction with prednisolone and PCSO-524® as supplementary treatment.
During the 10 months follow up, the dog showed improvement of clinical symptoms, no edema, lack of accumulation of fluid in abdomen cavity, and serum albumin that was increased to normal level.
Use of PCSO-524® and Cyclosporin for Treatment of Immune-Mediated Polyarthritis in Dogs
Authors:
An 8 years old Chihuahua dog was admitted to the Small Animal Hospital at Chulalongkorn University due to signs of depression, lethargy, lameness and joint effusion. Hematological examination and test of synovial fluid indicated Immune-Mediated Polyarthritis (IMPA).
Prednisolone, Gabapentin and Amoxillin-clavulanic acid were prescribed for the treatment. Abnormally increase of ALT, ALK and AST enzyme was observed 1 week later, therefore, the treatment was changed to Cyclosporin, Gabapetin, and PCSO-524®. The clinical signs continued to improve after the adjustment of prescription and Cyclosporin and Gabapetin were terminated after 3 and 4 months, respectively.
A follow-up examination at 4 months later showed no signs of lameness and joint effusion and no adverse effects caused by the long-term use of PCSO-524®.
The success of IMPA treatment is a result of rapid diagnosis and appropriate treatment protocol. Follow-up for treatment evaluation is necessary during the treatment course in order to reduce the impact on health and minimize the medication dosage without risk of causing adverse effects or recurrence of the disease.
PCSO-524® for Treatment of Immune-Mediated Polyarthritis in Dogs
Authors:
An 8-year old Chihuahua dog was admitted for surgical treatment of patella luxation at Small Animal Hospital of Chulalongkorn University, Thailand.
At 2 weeks prior to the hospital visit, the dog showed signs of fever, anorexia, lethargy, and lameness of the left leg. Non-steroidal anti-inflammatory drug (NSAIDs) was prescribed at that time but the dog had no response to the treatment.
The dog received prednisolone 0.6 mg/kg bid, gabapentin 10 mg/kg sid, samylin® liver supplement 1 tablet sid, and amoxicillin-clavulanic acid 20 mg/kg sid in the first week of the treatment. Then prednisolone was stopped due to elevation of liver enzymes; AST, ALT, and ALK.
The following 1-month treatment course included cyclosporine 6 mg/kg bid, gabapentin 10 mg/kg bid, samylin® 1 tablet sid, and PCSO-524® 1 capsule bid.
This article was summarized from the original article published in The Journal of Thai Veterinary Practitioners by the permission of Veterinary Practitioner Association of Thailand (VPAT)
Clinical study of PCSO-524 (ANTINOL™) as neutraceutical in canine allergic skin disease
Authors:
This study included 31 allergic dogs with chronic pruritis with other skin diseases excluded.
Dogs were split into 3 treatment groups based on degree of pruritis, distribution, extension of the lesions and skin and coat condition; Group 1: mild, Group 2: moderate, and Group 3: severe.
All dogs received PCSO-524 loading dose 10 mg/kg q12hr PO for 2 weeks followed by a maintenance dose of 10 mg/kg q24hr PO.
All dogs were evaluated at 2, 4, 8, 12 and 16 weeks for clinical response. The assessment made by the owners (PVAS Score) and Vets (CADESI-03 score).
Antinol® Case Study Contest 2017
10 Case Reports using PCSO-524® in combination with the treatment regimen for dogs and cats.
Pharmalink International Ltd. and Vetz Petz® would like to thank everyone involved in this 2017 Antinol® Case Study Contest competition and pay homage to our Professors and Veterinarians who have assisted in the judging of the competition.
This 2017 contest was very special with the inclusion of Professor Duncan Lascelles and the wonderful innovation of the live poll that the audience took part in to choose the Vets choice and favorite presentation.
Use of PCSO-524® Combined with Surgical Treatment of Patellar luxation in Dogs
Authors:
Five dogs with bilateral patellar luxation were presented at the Small Animal Hospital of Faculty of Veterinary Medicine, Chulalongkorn University.
Four dogs had grade 2, 3, and 4 medial patellar luxation in 3, 3, and 2 stifle joints, respectively. One dog had grade 3 bilateral lateral patellar luxation that had recurrent patellar luxation of left stifle joint for 6 months after previous surgery. All dogs had surgical treatment to re-align and stabilize extensor mechanism in the normal position.
The dogs received anti-inflammatory drug and PCSO-524® in combination with rehabilitation to restore normal limb function and muscle mass postoperatively. All dogs achieved good outcomes when compared with pre-operation. Range of motion was normal in all dogs and the patellae were in the normal position.
However, one stifle with previous reluxation and severe osteoarthritis had slightly crepitation when flexed and extended the stifle joint. Patellar luxation causes abnormal wear of the patella and trochlear ridges leading to lameness, muscle pain, and osteoarthritis.
The treatment focuses on stabilization of the stifle joint and restore limb function. Surgical treatment is recommended in most cases. Rehabilitation provides strengthen muscle, improves normal joint function, enhanceslimb function, and prevents complications.
Despite successful treatment for correcting patellar luxation, osteoarthritis remains occurrence in most cases.
Therefore, use of anti-inflammatory supplement such as PCSO-524® is important for long-term management with less side effect and safety for long-term use when compared with non-steroidal anti-inflammatory drugs.
Efficacy of PCSO-524® and prednisolone combination treatment for neck pain in Chihuahua dog with Chiari-like malformation and syringomyelia
Authors:
A 18-month-old male intact chihuahua presented with recurrent neck pain within 3 months after stop using prednisolone.
Upon physical and neurological examination, dog displayed pain and neck stiffness without neurological deficits. Radiographic findings of cervical spine was normal.
The dog was treated with prednisolone to relieve pain and inflammation and showed improvement of clinical signs. However, the recurrence occurred in 7 months with more severity. Magnetic resonance
imaging (MRI) demonstrated Chiari-like malformation and syringomyelia at C2-C4 and C7-T1 region.
PCSO-524® (VetzPetz Antinol®) was administered in combination with prednisolone and gabapentin. The clinical signs improved in 2 weeks so prednisolone was gradually reduced until discontinued but dose of PCSO-524® remained constantly. The dog was able to recover from neck pain and continued life activities as normal.
Long-term supplement of PCSO-524® (VetzPetz Antinol®) was effective for reducing inflammation of spinal cord in dog suffered from neck pain caused by syringomyelia.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
